Not logged in A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma El-Khoueiry, Anthony B.; Kim, Richard D.; Harris, William P.; Sung, Max W.; Waldschmidt, Dirk; Cabrera, Roniel; Garosi, Vittorio L.; Ploeger, Bart A.; Zebger-Gong, Hong; Brennan, Barbara J.; Wang, Ying A.; Mueller, Udo; Weispfenning, Anke; Seidel, Henrik; Coppieters, Sabine; Ishida, Tatiane C.; Galle, Peter R. Share Save
Share Save
Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial) Rauber, Conrad; Roberti, Maria Paula; Vehreschild, Maria J. G. T.; Tsakmaklis, Anastasia; Springfeld, Christoph; Teufel, Andreas; Ettrich, Thomas; Jochheim, Leonie; Kandulski, Arne; Missios, Pavlos; Mohr, Raphael; Reichart, Alexander; Waldschmidt, Dirk T.; Sauer, Lukas D.; Sander, Anja; Schirmacher, Peter; Jaeger, Dirk; Michl, Patrick; Dill, Michael T. Share Save
Therapy-relevant MDM2 amplification in cholangiocarcinomas in Caucasian patients Lyu, Su Ir; Plum, Patrick Sven; Fretter, Caroline; Simon, Adrian Georg; Bedau, Tillmann; Knipper, Karl; Thomas, Michael N.; Stippel, Dirk; Wagner, Britta Janina; Bruns, Christiane; Waldschmidt, Dirk; Buettner, Reinhard; Drebber, Uta; Quaas, Alexander Share Save
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024) Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Alguel, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V.; Kunzmann, V. Share Save
Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nalIRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts) Lahusen, A.; Lutz, M. P.; Karthaus, M.; Kirchner, M.; Cheung, P. F.; Wisser, S.; Ansorge, N.; Barmashenko, G.; Hoefling, S.; Leidig, T.; Schulte, M.; Waldschmidt, D. T.; Budczies, J.; Siveke, J. T.; Tannapfel, A.; Stenzinger, A.; Ettrich, T. J.; Eiseler, T.; Raeth, S.; Seufferlein, T. Share Save
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) (vol 7, 100552, 2024) Hartlapp, I.; Valta-Seufzer, D.; Siveke, J. T.; Alguel, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V.; Kunzmann, V. Share Save
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group Weiss, L.; Fischer, L. E.; Heinemann, V.; Gieseler, F.; Hoehler, T.; Mayerle, J.; Quietzsch, D.; Reinacher-Schick, A.; Schenk, M.; Seipelt, G.; Siveke, J. T.; Stahl, M.; Kaiser, U.; Waldschmidt, D. T.; Dorman, K.; Zhang, D.; Westphalen, C. B.; Boeck, S.; Haas, M. Share Save
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial Zhang, Danmei; Westphalen, C. Benedikt; Quante, Michael; Waldschmidt, Dirk T.; Held, Swantje; Kuetting, Fabian; Dorman, Klara; Heinrich, Kathrin; Weiss, Lena; Boukovala, Myrto; Haas, Michael; Boeck, Stefan; Heinemann, Volker; Probst, Victoria Share Save
Share Save
Predictive factors for treatment success of second-line NalIRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216) Lutz, M. P.; Ansorge, N.; Barmashenko, G.; Burkart, C.; Decker, T.; Ettrich, T. J.; von Weikersthal, L. Fischer; Geer, T.; Gerhardt, A.; Hoefling, S.; Jacobasch, L.; Karthaus, M.; Koenigsmann, M. P.; Leidig, T.; Schulte, M.; Schulte, N.; Schwarzer, A.; Siegler, G. M.; Waldschmidt, D. T.; Raeth, S. Share Save
Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy: A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group Weiss, L.; Heinemann, V.; Fischer, L.; Gieseler, F.; Hoehler, T.; Mayerle, J.; Quietzsch, D.; Reinacher-Schick, A.; Schenk, M.; Seipelt, G.; Siveke, J.; Stahl, M.; Vehling-Kaiser, U.; Waldschmidt, D.; Dorman, K.; Zhang, D.; Westphalen, B.; Haas, M.; Boeck, S. Share Save
Interim safety results from SEPION/AIO-PAK-0118: A multicenter, Phase I/II study of sequential epigenetic and immune targeting in combination with nabpaclitaxel/gemcitabine in patients with advanced pancreatic ductal adenocarcinoma Siveke, Jens T.; Sinn, Marianne; Boeck, Stefan; Siegler, Gabriele; Seufferlein, Thomas; Trojan, Joerg; Waldschmidt, Dirk; Koenig, Alexander; Schipp, Dorothea; Winkler, Ines; Liffers, Sven Thorsten; Kunzmann, Volker Share Save
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) Hartlapp, I; Valta-Seufzer, D.; Siveke, J. T.; Algul, H.; Goekkurt, E.; Siegler, G.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C. T.; Stang, A.; Kimmel, B.; Heinemann, V; Kunzmann, V Share Save
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol Ben Khaled, Najib; Seidensticker, Max; Ricke, Jens; Mayerle, Julia; Oehrle, Bettina; Roessler, Daniel; Teupser, Daniel; Ehmer, Ursula; Bitzer, Michael; Waldschmidt, Dirk; Fuchs, Martin; Reuken, Philipp A.; Lange, Christian M.; Wege, Henning; Kandulski, Arne; Dechene, Alexander; Venerito, Marino; Berres, Marie-Luise; Luedde, Tom; Kubisch, Ilja; Reiter, Florian P.; De Toni, Enrico N. Share Save
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC) Gebauer, Florian; Damanakis, Alexander Ioannis; Popp, Felix; Quaas, Alexander; Kutting, Fabian; Lutz, Katrin; Held, Swantje; Deuss, Burkhard; Goser, Tobias; Waldschmidt, Dirk; Bruns, Christiane Share Save
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group Perkhofer, L.; Striefler, J. K.; Sinn, M.; Opitz, B.; Goetze, T. O.; Gallmeier, E.; von Weikersthal, L. Fischer; Jacobasch, L.; Waldschmidt, D.; Niedermeier, M.; Sohm, M.; Sookthai, D.; Berger, A.; Beutel, A.; Seufferlein, T.; Ettrich, T. J. Share Save
IMMUTACE: A biomarker-orientated, multi center phase II AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC) Vogel, A.; Saborowski, A.; Hinrichs, J.; Ettrich, T. J.; Ehmer, U.; Martens, U. M.; Mekolli, A.; De Toni, E.; Berg, T.; Geissler, M.; Maenz, M.; Kirstein, M.; Waldschmidt, D. Share Save
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113) Hartlapp, I.; Valta-Seufzer, D.; Siveke, J.; Alguel, H.; Goekkurt, E.; Siegler, G. M.; Martens, U. M.; Waldschmidt, D.; Pelzer, U.; Fuchs, M.; Kullmann, F.; Boeck, S.; Ettrich, T. J.; Held, S.; Keller, R.; Anger, F.; Germer, C-T.; Stang, H. A.; Heinemann, V.; Kunzmann, V. Share Save
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study Tempero, M.; Oh, D-Y; Tabernero, J.; Reni, M.; Van Cutsem, E.; Hendifar, A.; Waldschmidt, D-T; Starling, N.; Bachet, J-B; Chang, H-M; Maurel, J.; Garcia-Carbonero, R.; Lonardi, S.; Coussens, L. M.; Fong, L.; Tsao, L. C.; Cole, G., Jr.; James, D.; Macarulla, T. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
BMC CANCER.png)
OAAI
.png){kind=icon}
Share.png){kind=icon}
Save